Farah Champsi
CIK 1198321 · last filed 2021-01-26
Farah Champsi is a corporate insider who has filed 20 SEC Form 4 insider transactions across 10 companies since 2008. The most recent filing, for PHICW, was dated Jan 26, 2021. Across all open-market trades the lifetime net is −$161.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $550.6M across reported positions. 40 SEC filings were submitted jointly with Guy P Nohra.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
ZSPH price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SAN FRANCISCO, CA 94111
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Population Health Investment Co., Inc. (PHICW) Delisted | Director | — | $0.00 | — | $0 | 1 | 2021-01-26 |
| Kite Pharma, Inc. (KITE) Delisted | Director | 66,074 | — | — | -$64.58M | 8 | 2017-06-22 |
| ZS Pharma, Inc. (ZSPH) Delisted | 10%+ Owner | 2,870,983 | — | — | -$117.94M | 2 | 2015-06-05 |
| TREVENA INC (TRVN) Delisted | Director | 7,024 | $0.01 | $78 | $10.00M | 1 | 2014-12-10 |
| Evofem Biosciences, Inc. (NEOT) Delisted | 10%+ Owner | 432,543 | — | — | $0 | 1 | 2014-12-01 |
| APPLIED GENETIC TECHNOLOGIES CORP (AGTC) Delisted | 10%+ Owner | 1,492,200 | $0.39 | $587.3K | $0 | 1 | 2014-11-19 |
| CHIMERIX INC (CMRX) Delisted | Director | 1,714,330 | $8.54 | $14.64M | -$6.94M | 2 | 2013-10-23 |
| PORTOLA PHARMACEUTICALS INC (PTLA) Delisted | Director | 1,116,214 | — | — | $0 | 1 | 2013-05-30 |
| Aegerion Pharmaceuticals, Inc. (AEGR) Delisted | 10%+ Owner | 165,140 | — | — | $844.9K | 1 | 2011-08-09 |
| CORT | 10%+ Owner | 5,043,299 | $109.17 | $550.58M | $17.60M | 1 | 2008-03-26 |
Recent Filings
20 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2021-01-26 | Population Health Investment Co., Inc. (PHICW) Delisted | Other (J) | — | $0 | EDGAR |
| 2017-10-05 | — | Mixed | −66,074 | -$11.06M | |
| 2017-06-22 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | +2,410 | $0 | EDGAR |
| 2017-06-16 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −20,450 | -$1.84M | EDGAR |
| 2017-05-01 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −19,168 | -$1.59M | EDGAR |
| 2017-04-26 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −123,913 | -$10.24M | EDGAR |
| 2017-04-17 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −115,376 | -$9.51M | EDGAR |
| 2016-06-03 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | +1,950 | $0 | EDGAR |
| 2015-07-02 | Kite Pharma, Inc. (KITE) Delisted | Sell (S) | −664,102 | -$41.40M | EDGAR |
| 2015-06-17 | Kite Pharma, Inc. (KITE) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.